MaxCyte Inc (NASDAQ:MXCT) is set to release its Q2 2025 earnings on August 6, 2025. The consensus estimate for Q2 2025 revenue is $9.57 million, and the earnings are expected to come in at -$0.10 per ...
MaxCyte, Inc. has announced the acquisition of SeQure Dx, a company specializing in assessing on-target and off-target gene editing for cell and gene therapies. This strategic move enhances MaxCyte's ...
MaxCyte, Inc. has announced preliminary financial results for the fourth quarter and full year of 2024, projecting core revenue between $8.3 million and $8.5 million for the fourth quarter, up from $7 ...
ROCKVILLE, Md. and ST. LOUIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (MXCT), (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing ...
A look at the shareholders of MaxCyte, Inc. (LON:MXCT) can tell us which group is most powerful. With 66% stake, institutions possess the maximum shares in the company. That is, the group stands to ...
FLORHAM PARK, N.J. and GAITHERSBURG, Md., May 25, 2021 /PRNewswire/ — Celularity, Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the ...
MaxCyte's fourth quarter and full year results are preliminary, unaudited and subject to change in connection with the completion of MaxCyte's quarterly and year-end closing processes and review ...
ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, ...
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results